MerTK/FLT3-specific small molecule inhibitors UNC2025, MRX2843 and UNC1666 were shown to have significant effect on tumor growth of AML, ALL and melanoma in cell lines, murine models and primary patient tumor samples [27,28,29,30]. Here, FLT3 is linked to acute myeloid leukemia.